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Cellular senescence limits the proliferative capacity of damaged cells and thereby acts as an 
intrinsic mechanism of tumor suppression. In this issue, Wajapeyee et al. (2008) identify insulin 
growth factor binding protein 7 (IGFBP7) as a secreted factor that mediates senescence induced 
by oncogenic BRAF in normal melanocytes. In addition, IGFBP7 triggers apoptosis in cells that 
have progressed to melanoma, suggesting a new approach for melanoma treatment.Replicative senescence was first 
described as a permanent state of pro-
liferative arrest occurring in cells after 
extended culture in vitro (Hayflick, 1965). 
Whereas replicative senescence is trig-
gered by telomere erosion, several other 
stress-inducing factors initiate a simi-
lar process, which occurs more rapidly 
than replicative senescence and without 
extensive cell division. This process, gen-
erally referred to as “cellular senescence,” 
acts as a program to limit the proliferative 
capacity of damaged cells. Stimuli that 
induce cellular senescence include DNA 
damage, oxidative stress, chemothera-
peutic drugs, and expression of certain 
activated oncogenes. Wajapeyee et al. 
(2008) now report that a secreted fac-
tor, insulin growth factor binding protein 
7 (IGFBP7), induces cellular senescence 
in melanocytes that contain activating 
mutations in the BRAF oncogene.
The first oncogene shown to trigger 
senescence was a tumor-derived allele 
of H-RAS (Serrano et al., 1997). At that 
time, the transforming activity of RAS 
in immortalized rodent cells was well 
established, and its ability to induce senescence in primary cells explained 
why these cells could not be transformed 
by RAS alone but required additional 
“immortalizing” factors, such as loss of 
tumor suppressor genes. Subsequent 
studies revealed that this occurs via sig-
naling through the MAPK cascade, and 
thus activated forms of RAF and MEK 
also produce similar phenotypes. More 
recent reports suggest that RAS-induced 
senescence involves a DNA-damage 
response induced by replication stress 
(Campisi and d’Adda di Fagagna, 2007). 
Thus, senescence may act to counter 
the tumor-promoting effects of hyper-
proliferative mutations and consequently 
is a “built-in” or intrinsic mechanism of 
tumor suppression (Lowe et al., 2004). 
Consistent with this view, execution of 
RAS-induced senescence requires the 
p53 and Rb tumor suppressor pathways 
(Serrano et al., 1997).
Although the physiological relevance 
of oncogene-induced senescence has 
been debated, recent reports indicate 
that this process acts as a potent barrier 
against tumorigenesis (Narita and Lowe, 
2005). As one example, melanocytic nevi Cell 13(moles) are premalignant lesions that are 
extremely stable and rarely progress, 
despite consisting of melanocytes con-
taining activating mutations in the BRAF 
gene (predominantly V600E, a glutamic 
acid to valine substitution at position 
600). Indeed, nevi contain cells showing 
hallmarks of senescence, and expression 
of BRAFV600E in cultured fibroblasts or 
melanocytes induces senescence. Mela-
nomas appear to acquire alterations that 
enable them to evade senescence. Con-
sequently, the senescence response halts 
the growth of benign neoplasms, thereby 
limiting their malignant progression.
In this issue, Wajapeyee et al. iden-
tify one mechanism by which onco-
genic BRAF triggers cellular senes-
cence in melanocytes. They conducted 
a genome-wide RNA interference (RNAi) 
screen to identify genes that are required 
for BRAFV600E to inhibit proliferation 
of human diploid fibroblasts and pri-
mary melanocytes. This screen led to 
the identification of a secreted protein, 
IGFBP7, that is required for the process. 
Expression of BRAFV600E in melano-
cytes induces synthesis and secretion 2, February 8, 2008 ©2008 Elsevier Inc. 339
Figure 1. IGFBP7 and BRAF-Induced Cellular Senescence
Early during melanoma progression, melanocytes acquire BRAF mutations that stimulate proliferation 
but also trigger senescence, in part, via enhanced secretion of insulin growth factor binding protein 7 
(IGFBP7). Silencing of IGFBP7 enables BRAF-expressing melanocytes to escape senescence and prog-
ress toward melanoma. The resulting melanoma cells remain sensitive to the induction of apoptosis by 
addition of IGFBP7.of IGFBP7, which then triggers senes-
cence as an autocrine/paracrine fac-
tor. Intriguingly, melanoma cells harbor-
ing activated BRAF genes often silence 
IGFBP7 expression, suggesting one way 
in which they bypass oncogene-induced 
senescence.
How does IGFBP7 execute its func-
tion? Wajapeyee et al. suggest that 
IGFBP7 acts through a negative feed-
back loop that attenuates the BRAF-
MEK-MAPK signaling cascade, leading 
to senescence in primary melanocytes 
and apoptosis in melanoma cells con-
taining BRAF mutations. A conceptually 
similar but mechanistically different feed-
back was recently suggested to account 
for senescence induced by disruption of 
the neurofibromatosis tumor suppressor, 
which also deregulates MAPK signaling 
(Courtois-Cox et al., 2006). By contrast, 
IGFBP7 induces apoptosis in melanoma 
cells with mutations in BRAF through 
increasing the expression of proapop-
totic proteins, SMARCB1 and BNIP3L. 
Why IGFBP7 induces senescence in 
primary melanocytes and apoptosis in 
melanomas remains a puzzle; neverthe-
less, studies suggest that oncogene-
expressing cells that have bypassed 
senescence, such as cancer cells, are in 
general more susceptible to induction of 
apoptosis (Lowe et al., 2004).
Previous work demonstrates that 
senescent cells display dramatic 
changes in their transcriptional profiles 
that distinguish them from growing or 
quiescent cells. In many instances, these 
changes involve upregulation of growth 
inhibitory proteins and downregulation of 340 Cell 132, February 8, 2008 ©2008 Elsevcell-cycle-promoting genes. However, in 
addition to these intuitive effects, senes-
cent cells also upregulate a class of 
genes encoding secreted factors such 
as matrix metalloproteinases, protease 
modulators, growth factors, and chemok-
ines. Although formerly used merely as a 
marker of senescence, the “senescence-
associated secretory phenotype” may 
be biologically significant, particularly 
with regards to the role of senescence in 
vivo. For example, secreted factors from 
senescent fibroblasts promote growth of 
adjacent epithelial cells (Krtolica et al., 
2001), suggesting that the secreted pro-
teins produce a microenvironment that 
favors malignant progression. By con-
trast, the secretory phenotypes of senes-
cent tumor cells can target these cells 
for clearance in vivo through an innate 
immune response (Xue et al., 2007), sug-
gesting a mode of immune surveillance 
that can have an antitumor effect.
Yet, until recently, the role of proteins 
secreted from senescent cells was not 
linked to the antiproliferative program 
per se. However, a recent study indi-
cates that one secreted protein, plas-
minogen activator inhibitor-1 (PAI-1), is a 
p53 target gene and acts together with 
p21, a cyclin-dependent kinase inhibi-
tor, to trigger senescence in both murine 
and human fibroblasts (Kortlever et al., 
2006). The findings by Wajapeyee et 
al. are even more remarkable because 
they suggest that one of these secreted 
factors (IGFBP7) is both necessary 
and sufficient to establish a senescent 
state. In both studies, the secreted fac-
tors ultimately interfered with mitogenic ier Inc.signaling, although in the case of PAI-1 
this impacted the PI3-kinase pathway, 
whereas with IGFBP7 the effects were 
largely on MAPK signaling.
The differences between the studies 
noted above suggest that the signal-
ing networks that trigger senescence 
can be highly context dependent, and it 
remains to be determined how universal 
the IGFBP7 mechanism is in the con-
trol of senescence and its relationship 
to other more established pathways of 
senescence. Moreover, it is not known 
whether other senescence-promoting 
lesions, for example, activation of RAS 
or loss of PTEN, also rely on IGFBP7. In 
fact, despite the canonical view that RAS 
and RAF function in a linear pathway, 
IGFBP7 has no effect on melanomas 
with activated RAS mutations. Further-
more, the two major senescence regula-
tors, p53 and p16INK4a, are apparently not 
involved in BRAF-induced senescence. 
These observations suggest key differ-
ences between RAS and BRAF signaling 
during senescence and perhaps other 
biological processes as well.
The new study has important impli-
cations for our understanding of mela-
noma progression (Figure 1). Indeed, the 
authors show that increases in IGFBP7 
occur in human benign nevi containing 
BRAF mutations, whereas this is not 
observed in human melanomas. Thus, 
IGFBP7 expression appears to be invari-
ably lost during melanoma progression, 
presumably allowing melanocytes to 
evade the senescence response to BRAF 
signaling. Undoubtedly, mutations that 
activate or repress cellular senescence 
will be crucial in the progression of many 
other human malignancies.
A great promise of research into the 
underlying mechanisms of apoptosis and 
cellular senescence is that this will sug-
gest strategies to harness the power of 
intrinsic tumor-suppressive mechanisms 
for improved cancer therapies. Clearly, 
Wajapeyee et al. suggest that this may 
be possible for melanoma, an extremely 
aggressive and chemo-resistant cancer. 
Specifically, the authors show that IGFBP7 
has a potent antitumor effect on xenograft 
tumors derived from BRAF mutated mela-
noma cells but has little if any effect on 
tumors containing wild-type BRAF. Per-
haps this suggests that cells with BRAF 
mutations become addicted to loss of 
IGFBP7, much as has been implied for cer-
tain tumor cells expressing the BCR-ABL or 
EGFR oncogenes (Sharma and Settleman, 
2007). Whether such stunning antitumor 
effects will be observed in human patients 
remains to be determined; nevertheless, 
these results demonstrate that key tumor-
suppressive mechanisms can operate via 
non-cell-autonomous mechanisms and 
provide proof-of-principle that this can be 
exploited therapeutically. The results also 
emphasize the utility of nonbiased genetic 
screening as an entry point to unexpected, 
and clinically useful, realms of biology.Life sciences research usually proceeds 
from conceptualization to experimenta-
tion and interpretation of data, which are 
often represented by bands on gels or 
mathematical data. New imaging meth-
ods now permit the visualization of cel-
lular events and phenomena in living 
cells and animals to allow researchers 
to confirm pure biochemical data and 
to follow individual cells. In this issue, 
Sakaue-Sawano et al. (2008) report new 
tools to visualize cell-cycle transitions. 
Their efforts illustrate how the union of 
biochemical knowledge with cell imag-
ing can give birth to a new method.
Cell growth occurs through an ordered 
sequence of events. The successive 
phases of the cell cycle are regulated 
through reversible phosphorylation 
involving different cyclin-dependent 
kinases (cdks) and by the periodic deg-
radation of cell-cycle-regulating proteins 
by the 26S proteasome. Proteasomal 
degradation is mediated by the cova-
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lent attachment of a ubiquitin chain by 
two ubiquitin ligases, the SCF and APC 
complexes. The APC complex is mainly 
active in mitosis and G1 and degrades 
proteins that hold back mitotic progres-
sion, whereas the SCF complex is active 
throughout the cell cycle on proteins 
marked by phosphorylation. In their 
work, Sakaue-Sawano et al. exploit the 
observation that two factors involved 
in the formation of prereplication com-
plexes, Cdt1 and Geminin, oscillate 
reciprocally during the cell cycle (Figure 
1) due to the activity of the APCCdh1 and 
SCFSkp2 complexes. Cdt1 helps to load 
the MCM helicase onto origins of DNA 
replication during the G1 phase of the 
cell cycle. Cdt1 begins to be degraded 
in human cells at the onset of S phase by 
SCFSkp2 (Li et al., 2003). In contrast Gemi-
nin, a negative regulator of Cdt1, accu-
mulates during S phase and is degraded 
when cells exit mitosis (Wohlschlegel et 
al., 2000; Nishitani et al., 2001).
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Sakaue-Sawano et al. first defined the 
parts of the Cdt1 and Geminin proteins 
that are required for their degradation 
and then fused these parts to two differ-
ent red and green fluorescent proteins. 
The careful design of the truncated Cdt1 
and Geminin constructs was crucial as 
it was important to prevent them from 
acting as dominant-negative regula-
tors. Therefore, both the domain of Cdt1 
interacting with Geminin and the domain 
of Geminin interacting with Cdt1 were 
removed. The choice of the fluorescent 
proteins fused to the truncated proteins 
was resolved by trying different combi-
nations. After lentiviral transfection of 
the two constructs in HeLa cells, stable 
transformants were obtained, which hap-
pen to be red during G1 (Cdt1) and switch 
to green (Geminin) during S phase. At 
the start of replication cells are yellow, 
in agreement with the existence of an 
overlap between the disappearance of 
Cdt1 and the appearance of Geminin. 
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